WFSBP Congress 2015

12thWorldCongressofBiologicalPsychiatry14–18june2015•Athens,GreeceMegaron Athens International Conference Centre

organisedby: WorldFederationofSocietiesofBiologicalPsychiatry

www.wfsbp-congress.org

HostedbytheHellenicSocietyfortheAdvancementofPsychiatryandrelatedSciences

InVItAtIonProGrAmmeCallforAbstracts/ScientificProgramme

WFSBP 2015

Table of Contents

Page

1 Invitationtothe12thWorldCongressofBiologicalPsychiatry

2 AboutWFSBP

3 AbouttheWFSBPCongress2015 Congress Administration WFSBP Executive Committee International Scientific Programme Committee National Presidents Local Organizing Committee

CongressProgramme 6 Preliminary Scientific Programme Schedule 7 Preliminary Scientific Programme23 Topics24 Call for Abstracts for Free Communications and Posters25 Format Descriptions26 WFSBP Awards27 Congress Information28 General Information

WFSBPGloBAlHeAdquArterSZum Ehrenhain 3422885 Barsbüttel, GermanyPhone: +49 – 40 – 670 882 90Fax: +49 – 40 – 670 328 82 91Email: info@wfsbp.orgwww.wfsbp-congress.org

ConGreSSVenueMegaron Athens International Conference CentreLeoforos Vasilissis Sofias and Kokkali 1Athens 115 21, Greecewww.maicc.gr

ConGreSSAndexHIBItIonoFFICe

Hamburg OfficeHanser & Co GmbHZum Ehrenhain 34 22885 Barsbüttel, GermanyPhone: +49 – 40 – 670 88 20Fax: +49 – 40 – 670 32 83Email: wfsbp2015@cpo-hanser.de

1

WFSBP 2015

Dear Colleagues,

It is our privilege and special pleasure to invite you to the 12th World Congress of Biological Psychiatry. The World Federation of Societies of Biological Psychiatry (WFSBP) has chosen Athens for its World Congress in June 14th –18th 2015.

Following the impressive success of the 12th Congress of Biological Psychiatry in Kyoto, a real milestone in the history of WFSBP, Athens is believed to be the ideal setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care.

Today, it is easy to envision a future where psychiatric diagnosis will be based on understanding funda-mental defects in thinking, emotional processing, and motivational systems. Psychiatry is now well positioned to take advantage of the major advances achieved in the last few decades in neurobiology and cognitive sciences and to build on them. WFSBP with its unique complementarity between basic neuroscientists and clinical psychiatrists, coming from various cultural and geographical backgrounds, is an important tool for the future of psychiatry.

During the upcoming World Congress of Biological Psychiatry, worldwide opinion leaders will share with us the recent innovations in their respective fields which impact on diagnosis, treatment and qua-lity of life of our patients. High scientific level sessions will be organized: plenary lectures, symposia, interactive workshops and debates. Young scientists are especially encouraged to present their recent findings through free communications and posters presentations.

A good number of chairpersons of WFSBP Task Forces have already committed themselves to actively participate in the scientific programme of the Athens Congress. However, we rely on the most meaning-ful participation of many colleagues from all over the world in order to make our next congress another milestone in WFSBP history. Thus, we are looking forward to welcome you in Athens, the heart of European culture and civilization, and to receive you according to the traditional Greek hospitality.

With our best personal regards

Prof. Constantin R. Soldatos Prof. Florence ThibautWFSBP President, Congress President and Chair of the InternationalChair of the Local Organizing Committee Scientific Programme Committee

Invitation to the 12th World Congress of Biological Psychiatry

Florence Thibaut

Constantin R. Soldatos

WFSBP 2015

2

Founded in 1974, the World Federation of Societies of Bi-ological Psychiatry is a non-profit world wide organisation composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.

With this multitude of countries represented in its world-wide community, the World Federation has built an inter-national network of over 4,000 opinion leaders, the majo-rity of which are key opinion-leaders in the practice of Biological Psychiatry.

WFSBPmemBerSPerContInent

As of September 2014

n Europe nAfrican Asia nMiddle Eastn South America nAustralian North America

tHePrInCIPleoBjeCtIVeSoFWFSBPAre:U To foster and encourage scientific research and advance-

ment in the field of Biological Psychiatry U To improve the quality of training spanning all the biolo-

gical psychiatry sciencesU To promote education and achieve the highest level of

knowledge and understanding within the fieldU To provide information and guidance to all institutions,

societies or individuals with an interest in biological psy-chiatry

U To establish, build, and maintain solid collaboration with international and national organisations related to biolo-gical psychiatry

Educational activities, regional, international and world con-gresses, the interactive website www.wfsbp.org, and The World Journal of Biological Psychiatry build the World Federation’s portfolio and insure its world-wide influence. The development of world-wide treatment guidelines is one of WFSBP’s main areas of international leadership.

WFSBPmemBerSPerFIeldoFACtIVIty

As of September 2014

Year after year, more and more professionals choose to join the World Federation’s Biological Psychiatry arena and en-joy its exclusive educational and networking opportunities. In the coming years WFSBP is looking forward welcoming new eminent member societies from different parts of the world.

n56,8 %

n 2,2 % n 0,4 %n4,8%

n 26 %

n 1,2 %

n8,6 %

About WfsBP

n Clinicians 88 % n Researchers 12 %

3

WFSBP 2015 WFSBP 2015

Congress AdministrAtionThe 12th World Congress of Biological Psychiatry will be organised by the World Federation of Societies of Biological Psychiatry (WFSBP)

WFsBP exeCutive CommitteePresident (2013 – 2015)Constantin R. Soldatos, Greecevice President (2013 – 2017)Tudor Udristoiu, RomaniaPast President (2013 – 2015)Florence Thibaut, FrancePresident elect (2013 – 2015)Masatoshi Takeda, Japansecretary (2013 – 2017)Lakshmi N. Yatham, Canadatreasurer (2013 – 2017)Martin Hatzinger, Switzerlandvice secretary (2013 – 2017)Ladislav Hosak, Czech Republicvice treasurer (2013 – 2017)Victoria Valdez, Ecuador

internAtionAl sCientiFiC ProgrAmme Committee (isPC)Florence Thibaut, France ChairPeter Falkai, Germany Co-ChairShigenobu Kanba, Japan Co-ChairLakshmi N. Yatham, Canada Co-ChairMichel Bourin, France Secretary

members of isPCC. A. Altamura, Italy*M. Bauer, GermanyA. Benyamina, France*M. Berk, Australia*J. Bobes, SpainC. L. Bowden, USAJ. Bradford, CanadaP. Brambilla, ItalyM. Bras, CroatiaM. S. Buchsbaum, USAD. Castle, AustraliaE. Ceskova, Czech RepublicJ. Ciprian-Ollivier, ArgentinaP. Cosyns, BelgiumP. Courtet, France*B. Dean, Australia

K. Fountoulakis, GreeceS. Frangou, UKW. Gaebel, GermanyF. Duarte Garcia, BrazilW. F. Gattaz, Brazil*M. George, USAB. Glenthoj, DenmarkP. Gorwood, FranceG. M. Goodwin, UKA. Grace, USAH. Grunze, UKA. Halaris, USAA. Hasan, Germany*C. Hiemke, GermanyE. Holsboer-Trachsler,SwitzerlandW. G. Honer, CanadaR. Kahn, The NetherlandsS. Kasper, AustriaT. Kato, JapanJ. Kane, USAJ. Kennedy, CanadaH. R. Kranzler, USA R. Lanzenberger, AustriaV. Larach, ChileA. Lopez Mato, ArgentinaC. Lyketsos, USAR. McCarley, USAM. Maes, BelgiumH. Mayberg, USAA. Kant Mital, IndiaE. Mohan Das, IndiaN. Müller, GermanyT. Murai, JapanCh. Pantelis, AustraliaG. Papadimitriou, GreeceT. Paparrigopoulos, Greece*O. Pogarell, GemanyR. Post, USA*M. Rapaport, USAM.S. Reddy, India*P. Riederer, GermanyR. Rupprecht, GermanyT. Saito, JapanM. Sarchiapone, ItalyN. Sartorius, SwitzerlandA. Schmitt, GermanyT. G. Schulze, Germany*

About the wfsbp Congress 2015

* Special correspondents of ISC Core Group

4

WFSBP 2015 WFSBP 2015

About the wfsbp Congress 2015

S. Seedat, South Africa*A. Seretti, ItalyE. Serfaty, ArgentinaL. Siever, USAN. Stefanis, Greece*J. Steiner, GermanyT. Suhara, JapanM.Takeda, JapanJ. Tellez-Vargas, ColombiaN. Venizelos, SwedenJ. Waddington, IrelandA. Weinstein IsraelP. Whybrow, USAY. Zervas, Greece*

Consultants to the ISPCG. Alexopoulos, USAC. Arango, Spain*E. Baca Garcia, SpainE. Belfort, VenezuelaA. Bozkurt, CyprusN. Boutros, USAP. Boyer, FranceA. Burns, UKR. Castilla-Puentes, USAM. Cetkovich-Bakmas, ArgentinaY. Hwa Chou, TaiwanH. Correa, BrazilJ. Costa e Silva, BrazilP. Cosyns, BelgiumJ. de Buitelaar, The NetherlandsM. Dierick, BelgiumB. Dubois, FranceP. Gejman, USAA. Germanavicious, LithuaniaA. H. Glassman, USAD. Gorelick, USAG. Hajak, GermanyS. Heckers, USA*Y. Hirayasu, JapanE. Hollander, USAJ. Horacek, Czech RepublicA. Jablensky, AustraliaC. Katona, UKW. Kaye, USAL. Konopka, USA

C. Krieg, GermanyT. Kudo, JapanJ. Soo Kwon, Korea*S. Lamy, FranceM. Leboyer, France M. Lejoyeux, FranceM. So Lee, KoreaB. Leonard, IrelandY. Levkovitz, IsraelP. Mc Gorry, AustraliaP. Mc Guire, UKA. Malafosse, SwitzerlandJ.-L. Martinot, FranceH. Y. Meltzer, USAA. Meyer-Lindenberg, GermanyZ. Nahas, LebanonD. Nutt, UKJ. Ospina-Duque, ColombiaN. Ozaki, JapanG. Parker, AustraliaL. Pezewas, AustriaS. G. Potkin, USAM. Rapaport, USAE. Richelson, USAJ. Rybakowski, PolandD. Rujescu, GermanyH. Sackeim, USAP. Salgado Pineda, SpainT. Schläpfer, GermanyL. Schneider, USAC. Schulz, USAE. Seifritz, SwitzerlandW. W. Shen, TaiwanL. Siever, USAD. St. Clair, UKM. Taleb, France/AlgeriaT. Taneli, USAJ. Treasure, UKN. A. Uranova, RussiaJ. Van Os, The NetherlandsD. Velakoulis, AustraliaE. Vieta, SpainX. Yu, China*M. Zanarini, USAJ. Zohar, Israel l

* Special correspondents of ISC Core Group

5

WFSBP 2015

About the WfsBP Congress 2015

nAtIonAlPreSIdentSA. Rivetti, ArgentinaA. Boyajyan, ArmeniaJ. Marksteiner, AustriaS. Claes, BelgiumN. D. Noya-Tapia, BoliviaA. Kucukalic, Bosnia-HerzegovinaP. Abreu, BrazilO. Atanasova Mikova- Demireva, BulgariaR. R. Lam, CanadaP. Rebolledo, ChileJ. Franco, ColumbiaR. Castro, Costa RicaM. Jakovljevic, CroatiaL. Hosak, Czech RepublicG. Wegener, DenmarkF. Solis de Mendez, Dominican RepublicV. Valdez de Vuibert, EcuadorA. Okasha, EgyptM. Meija Pena, El SalvadorJ. Harro, EstoniaP. Courtet, FranceA. Heinz, GermanyC. R. Soldatos, GreeceH. Soto Chavez, GuatemalaM. Aguilar Lopez, HondurasS.-W. Tang, Hong KongC. Banki, HungaryR. Nagpal, IndiaA. J. Tanra, IndonesiaG. Zalsman, Israel

M. Maj, ItalyT. Nishikawa, JapanM. Assimov, KazakhstanC. Uk Lee, KoreaB. Kupca, LatviaC. Baddoura, LibanonB. Stefanovski, MacedoniaS. Krishnaswamy, MalaysiaD. Moussaoui, MaroccoR. Castro-Roman, MexicoH. Lovdahl, NorwayM. Amin, PakistanG. Da Costa, PanamaL. Villalba, ParaguayE. Galli, PeruA. Wichniak, PolandJ. Relvas, PortugalT. Udristoiu, RomaniaN. Noznanoo, RussiaN. Maric Bojovic, SerbiaL. Vavrusova, SlovakiaS. Seedat, South AfricaM. Bernardo, SpainM. Msghina, SwedenM. Hatzinger, SwitzerlandCh.-Y. Liu, TaiwanP. Udomratn, ThailandB. Taneli, TurkeyA. V. Kalueff, UkraineA. D’Ottone, UruguayJ. Ibáñez-Domínguez, Venezuela

loCAlorGAnIZInGCommIttee(loC)Chair: C. R. SoldatosHonorary Chair: C. Stefanis

GeneralmembersD. AnagnostopoulosC. AndroutsosE. AngelopoulosN. BergiannakiP. BitsiosG. DiakogiannisD. DikeosA. DouzenisC. FokasK. FountoulakisG. GaryfalosA. GenaF. GourzisJ. HatzimanolisS. KaprinisG. KarantanosA. KarkaniasG. KolaitisS. KotsopoulosA. KoumoulaH. LazaratouM. Liakopoulou

M. MallioriV. MavreasG. MoussasG. NimatoudisM. PanagiotakopoulouG. PapadimitriouG. PapageorgiouC. PapageorgiouT. PaparrigopoulosE. PatsourisA. PolitisC. PsarrosP. SakkasM. SamakouriN. SmyrnisP. SkapinakisN. StefanisC. TouloumisE. VarsouA. VgontzasY. ZervasN. Zilikis

HonorarymembersN. AngelopoulosS. BeratisA. BotsisG. ChristodoulouI. GiouzepasC. IerodiakonouG. KaprinisA. KaravatosV. KontaxakisA. Liakos

I. LiappasM. LivaditisM. MadianosA. MailisY. PapakostasA. RabavilasG. TrikkasJ. TsiantisE. TzebelikosN. Vaidakis

WFSBP 2015

6

Preliminary scientific Programme schedule

technicalexhibitiontimes

Monday, 15 June 2015 09:00 – 17:00

Tuesday, 16 June 2015 09:00 – 17:00

Wednesday, 17 June 2015 09:00 – 17:00

Posterexhibitiontimes

Monday, 15 June 2015 09:00 – 17:00

Tuesday, 16 June 2015 09:00 – 17:00

Wednesday, 17 June 2015 09:00 – 17:00

Thursday, 18 June 2015 09:00 – 17:00

registrationCounter–openinghours

Sunday, 14 June 2015 12:00 – 19:00

Monday, 15 June 2015 07:30 – 18:30

Tuesday, 16 June 2015 08:00 – 18:30

Wednesday, 17 June 2015 08:00 – 18:30

Thursday, 18 June 2015 08:00 – 17:00

Sunday,14june monday,15june tuesday,16june Wednesday,17june thursday,18june

8:30

–

10:00

Symposia, Free Communication

Symposia, Free Communication

Symposia, Free Communication

Symposia, Free Communication

exH

IBIt

Ion

/Po

Ster

exH

IBIt

Ion

and

Gu

Ided

Po

Ster

to

ur

S

exH

IBIt

Ion

/Po

Ster

exH

IBIt

Ion

and

Gu

Ided

Po

Ster

to

ur

S

exH

IBIt

Ion

/Po

Ster

exH

IBIt

Ion

and

Gu

Ided

Po

Ster

to

ur

S

10:00 –

10:45Plenary Lecture Plenary Lecture Plenary Lecture Plenary Lecture

11:00

–

12:30

Symposia, Debates, Treatment Guidelines

Symposia, Debates, Treatment Guidelines

Symposia, Debates, Treatment Guidelines

Symposia, Round Table, Treatment Guidelines

reG

IStr

AtIo

n1

2:00

–1

9:00

13:15

–

14:45

Industry-Sponsored Sessions

Industry-Sponsored Sessions

Industry-Sponsored Sessions

Industry-Sponsored Sessions

15:00

–

16:30

Symposia, Treatment Guidelines

Symposia, Treatment Guidelines

Symposia, Treatment Guidelines

Symposia, Treatment Guidelines

16:30

–

18:00

Workshops,Free Communication

Workshops,Free Communication

Workshops,Free Communication

Closing Ceremony

from 17:00

Opening Ceremony,and Receptionand Networking Event

18:15

–

19:45

Industry-Sponsored Sessions

Industry-Sponsored Sessions

Industry-Sponsored Sessions

7

WFSBP 2015

Plenary Lecture, Debates, WfsBP Treatment Guidelines / Preliminary scientific Programme

oPenInGleCture

riskandresilienceforpsychosisandautism:dodevel-opmentalbrainchangesmatter?Chair: ConstantinR.Soldatos,GreeceSpeaker: ChristosPantelis,Australia/Greece

PlenAryleCtureS

dSm,ICdandrdocandthefutureofpsychiatricdi-agnosisChair: LakshmiYatham,CanadaSpeaker: MarioMaj,Italy

offlabeluseinpsychiatryChair: FlorenceThibaut,FranceSpeaker: GuyGoodwin,UK

neuropsychiatric syndromes of later life: ImplicationsforthestudyandtreatmentofmajorpsychiatricdiseasesChair: MasatoshiTakeda,JapanSpeaker: ConstantineLyketsos,USA/Greece

neurobiologicaloffearandanxietyanditsclinicalim-plicationsChair: MartinHatzinger,SwitzerlandSpeker: KerryRessler,USA

deBAteS

Isithelpfultotreatanxietypharmacologically?Proponent: MichelBourin,FranceOpponent: BorwinBandelow,Germany

Behavioraladdictions–normalityordeviance?Proponent: MarcPotenza,USAOpponent: PierVincenzoPiazza,France

Arechildrenovermedicated?Proponent: RobertPost,USAOpponent: TomInsel,USA

roundtABle

Isthereroomfornewpsychotropicdrugs?

WFSBPtreAtmentGuIdelIneS

taskForceonBipolardisordersImprovinglongitudinaltreatmentforbipolardisordersincludingmixedstatesguidelinesChair: SiegfriedKasper,AustriaPresenters:HeinzGrunze,Germany,EduardVieta,Spain, CharlesBowden,USA

taskForceonGeneticsChair: DanRujescu,GermanyCo-Chair: MickC.O´Donovan,UnitedKingdom

Genomicsofschizophrenia:resultsfromthelargestasso-ciationstudysofarMickC.O´Donovan,UnitedKingdom

thegeneticsofschizophrenia:BacktofamilystudiesLynnDelisi,USA

Geneticsofintermediatephenotypes:FocusoncognitionDanRujescu,Germany

ClinicalapplicationofpsychiatricpharmacogenetictestingJamesKennedy,Canada

taskForceonnosologyPsychopathology–past,presentandfutureChair: WolfgangGaebel,GermanyCo-Chair: VeronicaLarach,Chile

Psychopathologyandneuroscience:AmodularityapproachWolfgangGaebel,Germany

Afterjaspers,whatelse?MichaelMusalek,Austria

Gene-environmentinteractionandpsychopathologyGeorgeN.Papadimitriou,Greece

teachingpsychopathologytodayVeronicaLarach,Chile

taskForceonParaphiliasParaphiliatreatmentforadultsandadolescentsChair: FlorenceThibaut,FranceCo-Chair: PerBriken,Germany

theproposeddiagnosticcriteriaofparaphilicdisordersforICd-11PerBriken,Germany

WFSBPtreatementguidelinesonparaphiliasJohnM.W.Bradford,Canada

ethicalconsiderationsPaulCosyns,Belgium

Guidelinesondepression:GlobalizationorlocalizationChair: MichaelBauer,GermanyCo-Chair: RaymondW.Lam,Canada

WFSBPguidelinesforunipolardepressionEmanuelSeverus,Germany

GuidelinesformajordepressivedisorderinKorea

KangSeobOh,RepublicofKorea

Global guidelines for psychiatrists, local guidelines forgeneralpractitioners–mddguidelinesintaiwanChia-YihLiu,Taiwan

WFSBP 2015

8

Preliminary scientific Programme / symposia

CAnmAtdepressionguidelines:thenextgenerationofprogressRaymondW.Lam,Canada

taskForceonSchizophreniaChair: PeterFalkai,GermanyCo-Chair: AlkomietHasan,Germany

WFSBPGuidelinesontheacutetreatmentofschizophreniaAlkomietHasan,Germany

WFSBPGuidelinesonthelong-termtreatmentofschizo-phreniaThomasWobrock,Germany

taskForceonAddictivedisordersPresenters:MichaelSoyka,Germany KarlMann,Germany

SymPoSIA

Addictive disorders

Alcohol,nicotineandmetamphetamineaddiction,progressatbasicandclinicalfrontsChair: YousefTizabi,USACo-Chair: RosarioMoratalla,Spain

Alcoholandnicotineinteractions:Implicationsfordrinking-smokingco-morbidityYousefTizabi,USA

metamphetaminedamageofdopaminergicneuronsandmotorconsequencesRosarioMoratalla,Spain

Imaging and clinical intervention in metamphetamineaddictionHamedEkhtiari,Iran

Clinicalinterventionindrinking-smokingco-morbidityBoSöderpalm,Sweden

Behavioraladdictions:diagnosis,co-morbidityandneurobiologyChair: AvivWeinstein,IsraelCo-Chair: MarcPotenza,USA

Hypersexuality:obsessionoraddiction?FlorenceThibaut,France

A personal status, legal, economic and psychologicalcomparisonoftypesofadultmalegamblersPinhasDannon,Israel

doesfoodaddictionexist?MarcPotenza,USA

exerciseaddiction–brainandbehaviorAvivWeinstein,Israel

metabotropicglutamatereceptorsindrugandalcoholdependenceChair: AthinaMarkou,USACo-Chair: MarcusMunafo,UnitedKingdom

mGlur and mGlur7 activation, and mGlur5 blockademodulateconditionedbehavioralandneurochemicalef-fectsofpsychostimulantsinratsAthinaMarkou,USA

rescueofinfralimbicmGlur2deficitrestorescontrolofdrug seeking in alcohol dependent rats consistent withdecreased mGlur2 function in alcoholic patients andalcohol-dependentratsRainerSpanagel,Germany

reductioninmGlur5receptorbindinginhumansmok-ersandex-smokersdeterminedbypositronemissionto-mographyGregorHasler,Switzerland

Cognitive attentional bias for drug- and alcohol-relatedcues:studiesinnicotineandalcoholdependenthumansubjectsMarcusMunafo,UnitedKingdom

newchallengesinpsychoactivesubstancesandaddictionstreatmentsChair: AmineBenyamina,FranceCo-Chair: FrancoTagliaro,Italy

Clinicalefficacyofhighdoseofbaclofeninreducingalco-holconsumptionPhilippeJaury,France

Impact of chronic cannabinoid adolescent exposure onprefrontalstructureandfunctionThereseJay,France

new challenges for forensic toxicology from the “newPsychoactiveSubstances”FrancoTagliaro,Italy

Acutehumaneffectsofsyntheticcannabinoids:Howaretheyrelatedtocannabinoidreceptorligandproperties?DavidGorelick,USA

AntidepressAnts: BAsic / clinicAl

novelmechanismsofactionofantidepressanttreatmentChair: RainerRupprecht,GermanyCo-Chair: MarkRasenick,USA

lipidraftsandsignallingcascadesastargetsforantide-pressantsRainerRupprecht,Germany

9

WFSBP 2015

symposia / Preliminary scientific Programme

theroleoflipidraftsforantidepressantmediatedG-pro-teinsignallingMarkRasenick,USA

theroleofp-glycoprotein for theeffectsofantidepres-santsonHPAaxisCarminePariante,UnitedKingdom

thecytoskeletonasatargetforantidepressantsMassimilianoBianchi,Ireland

Antipsychotics: BAsic / clinicAl

AbetteruseofantipsychoticstoimprovetheprognosisofschizophreniaChair: MiquelBernardo,SpainCo-Chair: PhilippeCourtet,France

Pharmacogeneticofantipsychotics,asatooltoimproveresponsetocognitiveremediationRobertoCavallaro,Italy

Advantages of long-acting injectable antipsychotics (ineverydaylife)DieterNaber,Germany

relapse prevention and long-acting injectable antipsy-choticsinearlyphasesofschizophreniaEduardParellada,Spain

Interestofguidelinestoimprovetheeverydayuseofanti-psychotics:methodological,andimplementationaspectsPierre-MichelLlorca,France

d-aminoacidsandd-aminoacidoxidase(dAAo)basedmodulationofnmdArneurotransmission:diagnosticandtherapeuticimplicationsChair: KenjiHashimoto,JapanCo-Chair: Hsien-YuanLane,Taiwan

Preclinicalstudyofd-serinesignalinginschizophreniaKenjiHashimoto,Japan

d-aspartate based modulation of nmdAr neurotrans-mission:ClinicalimplicationAlessandroUsiello,Italy

d-amino acid oxidase (dAAo) based modulation ofnmdArneurotransmission:therapeuticimplicationHsien-YuanLane,Taiwan

d-amino acid oxidase (dAAo) activator levels in peri-pheralblood:diagnosticimplicationChieh-HsinLin,Taiwan

Anxiety disorders: BAsic / clinicAl

Anxietydisorders–clinicalandbiologicalmarkersindiagnosisandtreatmentChair: BorwinBandelow,GermanyCo-Chair: KatharinaDomschke,Germany

Patho-andtherapy-geneticsofanxietydisordersKatharinaDomschke,Germany

Childhoodanxietyasaprecursorofotherpsychiatricdis-ordersinadulthoodChristerAllgulander,Sweden

meta-analysisofalltreatmentsforanxietydisordersBorwinBandelow,Germany

theneedfornewtargetsinanxietydisorders:Fromneu-robiologytotreatmentNicJ.A.vanderWee,Germany

Sexdifferencesintheneurobiologyoffearandanxiety:AtranslationalapproachChair: MohammedMilad,USACo-Chair: RebeccaShansky,USA

Sex-specific behavioral and neuroanatomical profiles ofhigh-fearphenotypesRebeccaShansky,USA

SexdifferencesintheeffectsofstressonlearningLisaMaeng,USA

Cortisol and context-dependent extinction learning:differencesbetweenmenandwomenOliverWolf,Germany

Influenceofestrogenontheneuralcorrelatesoffearex-tinctionacrossspeciesKelimerLebron-Milad,USA

BipolAr disorders: BAsic / clinicAl

BiologicalandclinicalaspectsofmooddisorderswithpsychoticfeaturesChair: ThomasSchlaepfer,GermanyCo-Chair: PeterFalkai,Germany

BiomarkersassociatedwithpsychoticsymptomsinmajordepressionAlanSchatzberg,USA

VisualizationtechniquesandpsychoticpatternsPeterFalkai,Germany

Immunological and neuroimaging patterns associatedwithpsychoticdimensioninbipolardisorderCarloAltamura,Italy

PharmacologicaltreatmentofpsychoticmooddisordersHeinzGrunze,UnitedKingdom

WFSBP 2015

10

Preliminary scientific Programme / symposia

CAnmAtclinicalguidelinesforbipolardisorders2013:theevolutioncontinuesChair: LakshmiYatham,CanadaCo-Chair: RoumenMilev,Canada

Guidelines for clinical practice in bipolar disorders?overviewofthefieldKonstantinosFountoulakis,Greece

CAnmAt’s role indevelopingand implementingguide-linesforclinicalpracticeSagarParikh,Canada

CAnmAt/ISBdguidelines:2013updateRoumenMilev,Canada

thefutureofCAnmAt/ISBdguidelinesLakshmiYatham,Canada

majorcontroversiesforthetreatmentofbipolardisordersChair: GustavoVazquez,ArgentinaCo-Chair: EduardVieta,Spain

noveltreatmentsforbipolardisordersEduardVieta,Spain

optimal duration of atypical antipsychotic therapy formaintenancetreatmentLakshmiYatham,Canada

neuroprotectivepotentialofmoodstabilizersMichaelBerk,Australia

useofantidepressantsinbipolardisordersGustavoVazquez,Argentina

childhood & Adolescent disorders: BAsic / clinicAl

AdvancesinchildpsychiatryresearchChair: JosephBiederman,USACo-Chair: GaganJoshi,USA

Areautistictraitsclinicallymeaningful?JosephBiederman,USA

resting state functional connectivity analysis of socialnetworksinadolescentsandyoungadultswithhigh-func-tioningautismspectrumdisorderGaganJoshi,USA

resting-state functional connectivity in a longitudinalstudyofAdHdchildrengrownupMaiUchida,USA

memantineinthetreatmentofadultswithAdHdThomasSpencer,USA

majorpsychopathologyduringadolescenceandearlyadulthood:thedynamicdevelopmentalinterplaybetweenprotectiveandriskfactorsChair: PaoloBrambilla,ItalyCo-Chair: JairC.Soares,USA

Grin2b mediates susceptibility to affective problems inchildrenandadolescentsMariaNobile,Italy

developmentimagingandcognitivemarkersofpediatricParkinson’sdiseaseJairC.Soares,USA

Functionalimagingmarkersofpsychosisduringadoles-cenceVaibhavDiwadkar,USA

riskandprotectivefactorsforpsychopathologydetectedinthemannheimatriskStudy(mArS)ManfredLaucht,Germany

oxytocinandsocialcognition:FromsocialattachmentandrewardtonoveltreatmentsforautismChair: LarryYoung,USACo-Chair: AdamGuastella,Australia

oxytocin and social attachment: Implications for noveltherapiesforautismLarryYoung,USA

Interactions of oxytocin and serotonin in the striatummediatesocialrewardGulDolen,USA

Variation in the oxytocin receptor gene predicts facerecognitionabilitiesinfamilieswithanautisticchildDavidSkuse,UnitedKingdom

oxytocin therapies to treat core social impairments inautism:ClinicaltreatmenttrialsintoddlersandyouthAdamGuastella,Australia

cognitive neuroscience

Convergentapproachestoimpulsivity:theroleofnoradrenalineinAdHdandParkinson’sdiseaseChair: UlrichMüller,UnitedKingdomCo-Chair: AngieKehagia,UnitedKingdom

ChemicalneuroanatomyofAdHdandParkinson’sdis-ease–similaritiesanddifferencesManfredGerlach,Germany

PetimagingofthenoradrenergicsysteminAdHdandParkinson’sdiseaseRupertLanzenberger,Austria

11

WFSBP 2015

symposia / Preliminary scientific Programme

ImpulsecontroldisordersanddepressioninParkinson’sdisease–isthereanoradrenergiclink?LauraMarsh,USA

noradrenergicmodulationof impulsivity inParkinson’sdiseaseAngieKehagia,UnitedKingdom

dementiA: BAsic / clinicAl

ClinicalneurochemistryintheearlydiagnosisofdementiadisordersChair: PiotrLewczuk,GermanyCo-Chair: HenrikZetterberg,Sweden

Current status and new developments for Alzheimer’sdiseasebiomarkersKajBlennow,Sweden

diagnosticapproachesinfrontotemporallobardegener-ation(Ftld)MarkusOtto,Germany

Biomarkers for thediagnosis andprogressionofmotorandpremotorParkinson’sdiseaseBritMollenhauer,Germany

Blood biomarkers for neurodegenerative disorders –feasibleortoomuchofachallenge?HenrikZetterberg,Sweden

depression: BAsic / clinicAl

Identifyingbiomarkersoftreatmentoutcomeindepression:CanadiannetworkforbiomarkerintegrationindepressionChair: SidneyKennedy,CanadaCo-Chair: GregorHasler,Switzerland

BiomarkersandthefutureoftreatmentindepressionMadhukarTrivedi,USA

discoveringendophenotypesinmajordepressionGregorHasler,Switzerland

Genese: Pharmacological response to antidepressanttreatmentinthegeneralpopulationtreatedfordepressionNicolasRamoz,France

CAnBInd–updateontheprogresssofarSidneyKennedy,Canada

Inflammationandmitochondrialdysfunction:relevancetodepressionChair: MichaelBerk,AustraliaCo-Chair: OliviaDean,Australia

towardsdevelopmentofbiomarkersforpsychiatry:rele-vancetomitochondrialdysfunctionAnaCristinaAndreazza,Canada

theroleofinflammationinthebiologyandaetiologyofdepressionMichaelMaes,Thailand

targetingmitochondrialdysfunctionandoxidativestresstolowertheburdenofmooddisorders:Stateoftheevi-denceandfuturedirectionsPedroMagalhaes,Brazil

noveltherapiesfordepression:Anti-inflammatorytreat-mentsOliviaDean,Australia

molecularandgeneticsubstratesunderpinningdiagnosisofmajordepressionChair: YogeshDwivedi,USACo-Chair: DanRujescu,Germany

micrornA-mediated reorganization of gene expressionnetworksanditsroleindepressionpathogenesisYogeshDwivedi,USA

neurotrophic-andGABA-relatedcorticolimbicpathologyindepressionEtienneSibille,USA

dnAmethylationandchromatinremodelingincomplexphenotypeofmajordepressionGustavoTurecki,Canada

neuroticism:roleinnegativemoodstatesandinternaliz-ingdepressiveconditionsDanRujescu,Germany

novelbiomarkersinmooddisorders:opportunitiesfortranslationintoclinicalpracticeChair: BernhardBaune,AustraliaCo-Chair: KenjiHashimoto,Japan

A translational perspective on the neurotrophin hypo-thesisofdepressionMarcL.Molendijk,TheNetherlands

BdnF and its precursor proBdnF as biomarkers formooddisordersKenjiHashimoto,Japan

ApoptosisasnewbiomarkerformooddisordersYakupAlbay,Turkey

GeneticandserumimmunebiomarkersindepressionBernhardBaune,Australia

WFSBP 2015

12

Preliminary scientific Programme / symposia

Sleepandneuroplasticity:ClinicalimplicationsfordepressionChair: EdithHolsboer-Trachsler,SwitzerlandCo-Chair: AxelSteiger,Germany

AnimalmodelsofdisruptedsleepTarjaPorkka-Heiskanen,Finland

SleepandsynapticdysfunctionindepressionAnneEckert,Switzerland

SleepaspredictorofemotionalregulationinchildrenMartinHatzinger,Switzerland

Sleep-eeGderivedbiomarkersofdepressionAxelSteiger,Germany

epidemiology

latencytopharmacologicaltreatmentsinpsychiatricdisorders:epidemiological,biologicalandclinicalaspectsChair: CarloAltamura,ItalyCo-Chair: MarionLeboyer,France

duration of untreated bipolar disorder: missed oppor-tunitiesforoptimaltreatmentMarionLeboyer,France

Assessinglatencytopharmacologicaltreatmentsinpsy-chiatricdisorders:differencesbetweenaffectiveandpsy-choticdisordersBernardoDell´Osso,Italy

BiologicalfindingsinrelationtountreatedschizophreniaJariTiihonen,Finland

theeffectofprolongeddurationofuntreateddepressiononantidepressanttreatmentoutcomeLarsVedelKessing,Denmark

genetics

AdvancesingeneticsofaffectivedisordersChair: GeorgeN.Papadimitriou,Greece

updateongeneticsofaffectivedisordersDimitrisDikeos,Greece

PharmacogeneticsofantidepressantsAlessandroSerretti,Italy

organizationandadministrationofamultinationalpro-jectonpharmacogeneticsDanielSurrey,Belgium

overviewofthefieldandcriticalappraisalsThomasSchulze,Germany

epigeneticacquisitionsinmooddisorders:ImplicationforpathophysiologyandtreatmentChair: CarloAltamura,ItalyCo-Chair: TomasEkstrom,Sweden

role of epigenetic modulation in psychiatric disorders:thestateofartTomasEkstrom,Sweden

epigeneticregulationofBdnFgeneinbipolarvs.unipo-lardepressivedisordersBernardoDell´Osso,Italy

epigeneticmechanismsandendocannabinoidsignaling:Aputativetreatmentforpsychiatricdisorders?MauroMaccarone,Italy

PossiblemechanismsandbiologicaltargetsforepigeneticmodulationinpsychiatricdisordersClaudioD´Addario,Italy

Immunogenetics:exploringnewterritoryinschizophreniaChair: JamesKennedy,CanadaCo-Chair: JenniePouget,Canada

Hypothesis-drivengenome-wideassociationstudyidenti-fiesimmunegenesassociatedwithschizophreniaJenniePouget,Canada

new data to investigate an old epidemiological puzzle:the negative association between schizophrenia andrheumatoidarthritisNaomiWray,Australia

extremestructuralvariationofthehumanHlAlocusanditsrelationshiptoschizophreniariskStevenMcCarroll,USA

themicrobiome:themissinglinkinthepathogenesisofschizophreniaRobertYolken,USA

moleculAr neuroBiology

BiomarkersinpsychiatricdisordersChair: PeterRiederer,GermanyCo-Chair: FlorenceThibaut,France

BiomarkersinschizophreniaPeterFalkai,Germany

BiomarkersinAdHdEdnaGrünblatt,Switzerland

BiomarkersinalcoholismToshikazuSaito,Japan

BiomarkersinAlzheimer‘sdiseaseMarkusSchwarz,Germany

13

WFSBP 2015

symposia / Preliminary scientific Programme

Glutamatergicmechanismsinschizophrenia:FromketaminetogeneticmodelsChair: PeterGass,GermanyCo-Chair: KazutoshiNakazawa,USA

Ketaminereversal:towardsempiricaldiscoveryofanti-psychoticswithneuroimagingPhilipCorlett,USA

expressionanalysisofanmdAmK-801ratmodelidenti-fiesnovelcandidategenesforschizophreniaDanRujescu,Germany

mechanismsofneuronalsynchronydeficits innmdAr-hypofunction-mediatedschizophreniamousemodelKazutoshiNakazawa,USA

Inducible genetic mouse models to study the onset ofschizophreniaduringlateadolescenceDragosInta,Germany

neuron-Gliainteractionsandneuropsychiatricdisease:ImplicationsfornoveltherapeuticsChair: ThomasSedlak,USACo-Chair: Jean-PierreMothet,France

d-serine and glycine in gliotransmission: Synaptic andextra-synaptictargetsJean-PierreMothet,France

neuron-astrocyteinteractions–acriticaljuncturewheregene-environmentinteractionsincreaseriskofpsychiatricdiseaseMikhailPletnikov,USA

relation of inflammatory cytokines, astrogliosis mark-ersandprefrontalgreymattervolumeinschizophreniasubgroupsVibekeCatts,Australia

Interplay of neurons and glia for glutamate and gluta-thionecycling–newavenuestotargetexcitatoryneuro-transmissionabnormalitiesinneuropsychiatricdisordersThomasSedlak,USA

neuropAthology

understandingpsychiatricdisorders:recentadvancesinpostmortemresearchChair: BrianDean,AustraliaCo-Chair: ElizabethScarr,Australia

StructuralandmolecularalterationsofthehippocampusinschizophreniaPeterFalkai,Germany

rolesforimmune-regulatedgenesandneurotransmitterreceptorsinthepathophysiologyofpsychiatricdisordersBrianDean,Australia

thesyndromeofschizophrenia:Progresstowardspoten-tialbiomarkersElizabethScarr,Australia

Autophagyasfuturetreatmenttargetforschizophrenia:lessonsfromactivity-dependentneuroprotectiveproteinIllanaGozes,Israel

neuroimAging: genetic, FunctionAl, structurAl

Biologicaloverlapsbetweenschizophreniaandautismspectrumdisorders:neuroimagingandneurophysiologyChair: SergeMitelman,USACo-Chair: MonteBuchsbaum,USA

neural correlates in autism spectrum disorders andschizophreniaJunkoFukushima,Japan

Positron emission tomography in patients with schizo-phreniaandautismspectrumdisordersMarie-CécileBralet,France

Srgap3-/mice present a neurodevelopmental disorderwithschizophrenia-relatedandautism-relatedintermedi-atephenotypes:ImplicationsforpsychiatryRobertWaltereit,Germany

mrIanddiffusiontensorimagingassessmentofpatientswithschizophreniaandautisticdisorderMonteBuchsbaum,USA

BrainimagingandtreatmentreponseChair: SiegfriedKasper,AustriaCo-Chair: LarsFarde,Sweden

multimodalimagingandtreatmentresponseindepressionSiegfriedKasper,Austria

targetsfordeepbrainstimulationindepressionThomasSchlaepfer,Germany

d2-receptoroccupancyandtreatmentreponseinschizo-phreniarevisitedLarsFarde,Sweden

Imagingoftheglutamatergicneuroreceptors,anewtarget?ErichSeifritz,Switzerland

WFSBP 2015

14

Preliminary scientific Programme / symposia

developmentofbiomarkersforneuropsychiatricdisorders:State-of-the-artandchallengesaheadChair: NikolaosKoutsouleris,GermanyCo-Chair: ChristosDavatzikos,USA

neurocognitiveandimaging-basedmodelofnormalandabnormalbrainmaturationfromchildhoodtoearlyadult-hoodTedSatterthwaite,Germany

machinelearningbiomarkersforindividualizedoutcomepredictioninfunctionalpsychosesLenaPalaniyappan,UnitedKingdom

Geneticmarkersofautism-spectrumdisordersChristosPantelis,Australia

diagnosticandprognosticimagingmarkersinneurode-generativedisordersStefanKlöppel,Germany

neuroimagingandriskforschizophreniaChair: LynnDelisi,USACo-Chair: MarekKubicki,USA

neuroimaginginpeopleatultrahighriskforpsychosisPhilipMcGuire,UnitedKingdom

mechanismsunderlyingbrainchangesinearlypsychosisChristosPantelis,Australia

earlychildhoodbraindevelopmentinchildrenatriskforschizophreniaJohnGilmore,USA

newwhitematterbiomarkersofschizophreniariskMarekKubicki,USA

neurophysiology

neuraloscillations:translationalresearchinpsychiatryChair: ToshiakiOnitsuka,JapanCo-Chair: RobertMcCarley,USA

neuraloscillations:optogeneticstudiesinmiceRobertMcCarley,USA

Findingsofauditorysteady-stateresponsesinpsychiatricdisordersToshiakiOnitsuka,Japan

neuraldynamicswithsimultaneouseeGandfmrImea-surementHiroakiMizuhara,Japan

nmdA-r hypofunctioning and dysregulated high-fre-quencyoscillationsinschizophreniaPeterUhlhaas,UnitedKingdom

SerotoninandneuroplasticityChair: RupertLanzenberger,AustriaCo-Chair: ChristophKraus,Austria

effectsofserotoninonneurostimulationinducedcorticalplasticityWalterPaulus,Austria

SerotoninandneuroplasticityEeroCastren,Finland

Serotonin and neuroplasticity investigated in vivo withneuroimagingChristophKraus,Austria

neuralplasticityintheetiologyandtherapyofpsychiatricdisordersTiloKircher,Germany

pAin: BAsic / clinicAl

resolvingthemissinglinkbetweenphysicalandmentalpain:Basic,clinical,andtranslationalapproachesChair: ShigenobuKanba,JapanCo-Chair: TimSalomons,UnitedKingdom

ComorbidityofpsychiatricdisordersinchronicpainRyotaHashimoto,Japan

microgliaasapainmaker inneuropathicpain:rodentstudiesMakotoTsuda,Japan

therapeutic and neuroimaging approaches to physicalandmentalpainTimSalomons,UnitedKingdom

microgliaasapossiblekeyplayer tobindphysicalandpsychologicalpain:translationalapproachShigenobuKanba,Japan

15

WFSBP 2015

symposia / Preliminary scientific Programme

phArmAcology

Crossspeciesstudiesofpsychedelicdrugs–relevancetopsychiatricdisordersChair: FranzVollenweider,SwitzerlandCo-Chair: MarkA.Geyer,USA

BehavioralandpharmacologicalstudiesofpsychedelicsinanimalsMarkA.Geyer,USA

disruption of thalamocortical activity in psychedelicmodelsinanimalsFrancescArtigas,Spain

eeGpowerspectraandconnectivitychangesinpsychedelicanimalmodelsTomasPalenicek,CzechRepublic

neuroimaging and behavioral studies of cognitive andemotionaleffectsofserotonergichallucinogensinhumansFranzVollenweider,Switzerland

therapeuticdrugmonitoring,pharmacogeneticsandbrainimagingmethodsastoolsforimprovingpharmacotherapyChair: ChristophHiemke,GermanyCo-Chair: ChinBinEap,Switzerland

PharmacogeneticsforimprovingpharmacotherapiesChinBinEap,Switzerland

therapeutic drug monitoring for improving pharmaco-therapiesChristophHiemke,Germany

BrainimagingtechnologiesinpsychiatryGerhardtGründer,Germany

toolsforimprovingpharmacotherapyinpsychiatry:theopinionofaclinicianAndreasConca,Germany

theimportanceofpharmacovigilanceinpsychiatricinpatientpopulationsChair: StefanBleich,GermanyCo-Chair: AnastasiosKonstantinidis,Austria

Systematicpharmacovigilanceinpsychiatry–Isitnec-essary?SerminToto,Germany

Suicidalityduringantidepressanttreatmentinapsychia-tricinpatientpopulationSusanneStübner,Germany

restlesslegssyndromeinducedbypsychotropictreatmentKonstantinosPapageorgiou,Austria

Polypharmacyinpsychiatry–ariskfactorforadverseevents?AnastasiosKonstantinidis,Austria

pregnAncy, post pArtum And new Born: BAsic / clinicAl

recentadvancesinunderstandingandtreatingpsychiatricdisordersinpregnancyandpostpartumChair: SimoneVigod,CanadaCo-Chair: MeirSteiner,Canada

Investigating thephenotypicandgenotypicheterogene-ityofpostpartumdepressioninaninternationalperinatalpsychiatryconsortiumSamanthaMeltzer-Brody,USA

PreeclampsiaandriskofpostpartumpsychiatricepisodesTrineMunk-Olsen,Denmark

PregnancyoutcomesamongwomenusingantipsychoticdrugsSimoneVigod,Canada

transcranial magnetic stimulation for pregnant womenwithmajordepressivedisorderDeborahKim,USA

psychoneuroimmunology

diagnosticandprognosticstratificationofaffectivedisordersbasedoninflammationbiomarkersandimmunerelatedneurotransmitterpathwaysChair: AngelosHalaris,USACo-Chair: Aye-MuMyint,Germany

StratificationandoutcomepredictionofdepressedpatientsusingpanelsofinflammationbiomarkersAngelosHalaris,USA

Canplasmalevelsofkynureninesassistinthestratifica-tionofmooddisorders?Aye-MuMyint,Germany

Inflammation-induced disturbances of neurotransmitterprecursoraminoacidsandtheirpossibleroleasbiomark-ersindepressionBarbaraSperner-Unterweger,Austria

Biomarkerandtherapeuticpotentialoftheendocannabi-noidsysteminneuroinflammation-relatedpsychosesRafaelFranco,Spain

WFSBP 2015

16

Preliminary scientific Programme / symposia

psychopAthology

Psychobiologyofmen’smentalhealthChair: LeoSher,USACo-Chair: ZoltanRihmer,Hungary

theWFSBPmen’smentalHealthtaskForce:rationaleforaneuroendocrine-focusedapproachtomen’smentalhealthTimothyRice,USA

depressioninmen:ClinicalandphenomenologicalaspectsWolfgangRutz,Sweden

Suicideinmen:HormonalandneurobiologicalcorrelatesZoltanRihmer,Hungary

testosterone,violenceandhomicideLeoSher,USA

schizophreniA: BAsic / clinicAl

BiologicmarkersofcognitivedeficitsandnegativesymptomsinschizophreniaChair: NashN.Boutros,USACo-Chair: AdamWichniak,Poland

Cognition in schizophrenia: need for computationalmodelingtoidentifybiologicalmarkersAndreasHeinz,Germany

need for assessment batteries to examine cognition indeficitsyndromepatientsNashN.Boutros,USA

negativesymptomsinschizophrenia:mainissuesinthesearchforbiomarkersSilvanaGalderisi,Italy

quantitativeanalysisofneurophysiologicalsignalsasbi-ologicalmarkerofcognitivedeficitsandnegativesymp-tomsinschizophreniaAdamWichniak,Poland

CentralroleofglialcellsinthepathogenesisofschizophreniaChair: RobertSchwarcz,USACo-Chair: InaWeiner,Israel

microglia:Acommontargetfordiversedrugspreventingschizophrenia?InaWeiner,Israel

Prenatal elevation of the glia-derived neuromodulatorkynurenicacid:AnovelschizophreniamodelRobertSchwarcz,USA

ActivationofmicrogliaandastrocytesinschizophreniaislinkedtoincreasesinbraincytokinesKatarinaZavitsanou,Australia

Astrocytic dopamine modulates neuronal network andcognitivefunctionsintheprefrontalcortexJean-PierreMothet,France

Computational,cognitiveandpharmacologicalconnectomics:towardsunderstandingmechanismsofpsychosisChair: AlanAnticevic,USACo-Chair: DeannaBarch,USA

Integratingpharmacology,computationandconnectivitytounderstandschizophreniaonsetandprogressionAlanAnticevic,USA

Connectomicsofpsychosis:Crossdiagnosticsimilarities,differencesandrelationshipstordoCdimensionsDeannaBarch,USA

neural oscillations in meG-data: A translational per-spectivePeterUhlhaas,UnitedKingdom

elucidatingbiomarkersofriskforandprogressiontopsy-chosisusingneuroimagingTyroneCannon,USA

definingandre-definingtheboundariesofpsychoticdisordersusingneuroimagingChair: ChristosPantelis,AustraliaCo-Chair: NikolaosKoutsouleris,Germany

decomposing schizophrenia into intermediate imagingphenotypesidentifiedbymultiplesystemmappingHenrikWalter,Germany

IdentifyingneuroanatomicalsignaturesofschizophreniaphenotypesusingnovelimagingmethodsChristosDavatzikos,USA

Stratifying schizophrenia according to outcome usingmrI-basedpatternclassificationmethodsPaolaDazzan,UnitedKingdom

Commonalities and differences between schizophreniaand neurodegenerative disorders elucidated by neuro-imagingDennisVelakoulis,Australia

dysregulationoftyrosinetransportinfluencedopaminefunctionandcausecognitivedeficitsinschizophreniaChair: NikolaosVenizelos,SwedenCo-Chair: GeorgeE.Jaskiw,USA

Aberrant tyrosine transport in fibroblast from patientswithschizophreniaandbipolar-IdisordersNikolaosVenizelos,Sweden

17

WFSBP 2015

symposia / Preliminary scientific Programme

Aberrant tyrosine transport in fibroblast from patientswithschizophrenia–indicationofmaternalinheritanceLennaFlyckt,Sweden

tyrosinedepletionlowersinvivodoPAsynthesisinven-tralhippocampusGeorgeE.Jaskiw,USA

Acomparativegenomicmeta-analysisstudy focusedongenesandmechanismsinvolvedinaminoacidtransportinschizophrenicandbipolardisorderpatientsFragiskosKolisis,Greece

newinsightsofclinical,neurobiologicalandgeneticaspectsinmentalillnessChair: ThomasSchulze,GermanyCo-Chair: RyotaHashimoto,Japan

CurrentgeneticapproachestomajorpsychiatricdisordersThomasSchulze,Germany

recentadvancesinneuroinflammationrelevanttoschiz-ophreniatherapeuticsThomasWeickert,Australia

newgliaworldtopsychiatry:BrainfunctionandmentaldisordersManabuMakinodan,Japan

IntermediatephenotypestrategyfordiscoveringdiseaserelatedgenenetworkRyotaHashimoto,Japan

nitricoxide,glutamateandschizophrenia:newinsightsChair: DragosInta,GermanyCo-Chair: AndreasReif,Germany

nitricoxideandzinclevelsinlimbicregionsinpre-andpost-pubertal rats after neonatal lesions of the ventralhippocampusGonzaloFlores,Mexico

noS1-noS1AP interaction at the glutamatergic post-synapseasacandidatemechanismin thepathogenesisofschizophreniaAndreasReif,Germany

theglutamatereceptorcomplexinschizophreniapatho-genesisandtreatmentDavidBredt,USA

the islands of Calleja: the substrate for the glutama-te-nitricoxide-dopaminelinkinschizophrenia?DragosInta,Germany

Sleep,spindles,andschizophreniaChair: RobertMcCarley,USACo-Chair: GulioTononi,USA

SleepspindledeficitspointtothalamicreticularnucleusdysfunctioninschizophreniaGulioTononi,USA

optogeneticstudiesoftheroleofthethalamicreticularnucleusinspindles:ImplicationsforschizophreniaRobertMcCarley,USA

Sleepspindles,magneticresonancespectroscopyinthethalamusandcognitivefunctioningRetoHuber,Switzerland

Amathematicalmodelforasleepspindleanditsappli-cationtothequantificationofclozapineeffectsonsleepspindlesinschizophreniaPeriklisKtonas,Greece

theimpactoftobaccoandcannabisuseonpsychosisliabilityandillnesslongtermoutcome:epidemiologicalevidenceacrosseuropeandAustraliaChair: NikosC.Stefanis,GreeceCo-Chair: DavidCastle,Australia

tobaccoandcannabislongtermimpactonphysicalhe-althandclinicaloutcomesinschizophrenia.Isdisconti-nuationofsubstanceusefeasible?DavidCastle,Australia

Substanceusebringsforwardtheonsetofnon-affectivepsychosis: Potential biological mechanisms and clinicalimplicationsNikosC.Stefanis,Greece

How high potency cannabis (Sinsemilla/Skunk) use hasreshapedtheassociationbetweencannabisandpsychosisMartaDiForti,UnitedKingdom

environmentalexposuresandfamiliarriskforpsychosis:making senseofdifferential sensitivity to the effects ofcannabisJimvanOs,Netherlands

alpha4beta2-nicotinicacetylcholinereceptorsinschizophrenia:ImplicationsforsmokingcessationandtherapeuticsChair: IrinaEsterlis,USACo-Chair: EdenEvins,USA

nicotine dependence treatment in schizophrenia: evi-denceforeffectivenessofmaintenancepharmacotherapyEdenEvins,USA

WFSBP 2015

18

Preliminary scientific Programme / symposia

neuroscienceofnicotineaddictionvulnerabilityinschizo-phreniaAndrewChambers,USA

Invivoevidence forbeta2-nAChrupregulation insmo-kerswithschizophreniaIrinaEsterlis,USA

nicotinicCHrnA4genotypepredictsclinicaloutcomeinschizophreniaandneurolepticdrugtreatmentresponseGeorgWinterer,Germany

stimulAtion methods (ect, tms, vns, dBs)AdvancesinrepetitivetranscranialmagneticStimulation(rtmS)astreatmentforpsychiatricdisordersChair: DavidGorelick,USACo-Chair: ChristosTheleritos,Greece

Functional connectivity-based strategy of neuromodula-tionformajordepressionMotoakiNakamura,Japan

deeptranscranialmagneticstimulationinmajordepres-sion:FromanimalmodelstoclinicalapplicationYechielLevkovitz,Israel

Intermittentthetaburstprotocolforrestrictedandrepeti-tivebehavioronhighfunctionautisticspectrumdisorderMarcoMarcolin,Brazil

neuroplasticeffectsofstandardanddeeptmStreatmentasmeasuredbyeeGinindividualswithattention-deficithyperactivitydisorder(AdHd)AbrahamZangen,Israel

ClinicalapplicationsandtechnicalfoundationsoftranscranialdirectCurrentStimulation(tdCS),anon-invasivebrainstimulationtherapy,inpsychiatricdisordersChair: AndreBrunoni,BrazilCo-Chair: EmmanuelPoulet,France

tdCSinpsychiatry:mechanisticfoundationsandcurrentchallengesMichaelNitsche,Germany

tdCSforneuromodulationofdecision-making:Implica-tionsfortheaddictivebrainShirleyFecteau,Canada

ClinicalandbiologicalevidenceforusingtdCSinschizo-phreniaJeromeBrunelin,France

tdCSinmajordepressivedisorder:resultsfromrando-mizedclinicaltrialsandfollow-upstudiesAndreBrunoni,Brazil

IdentifyingthebiologicaltargetsoftreatmentresponsetoneuromodulationinresistantpsychiatricdisordersChair: ZafirisDaskalakis,Canada

neurophysiologicalandsymptomaticchangesinducedbymagneticseizuretherapyinschizophreniaZafirisDaskalakis,Canada

Cognitive,structuralandconnectivitychangesfromrepe-titive magnetic stimulation to the prefrontal cortex inschizophreniaAristotleVoineskos,Canada

eCt-Inducedchangesinfunctionalconnectivityintreat-mentresistantdepressionGeorgiosPetrides,USA

Changes in brain connectivity associated with medialforebrainbundledBSindepressionThomasSchlaepfer,Germany

recentresearchdatainelectroconvulsivetherapyandhowtheyinformstateoftheartclinicalpracticeChair: GeorgiosPetrides,USACo-Chair: DeclanMcLoughling,Ireland

theeFFeCt-deptrial:Bitemporalvs.high-doserightuni-lateralelectroconvulsivetherapyfordepressionDeclanMcLoughling,Ireland

Antidepressant efficacy of rul-ultra brief pulse eCt:datafromphaseIofthePrIdestudyCharlesKellner,USA

differentialresposetoeCtbetweenunipolarandbipolardepressionPascalSienaert,Belgium

KetaminepluseCt:Synergisticeffectsinthetreatmentofdepression?StylianiKaliora,USA

19

WFSBP 2015

symposia / Preliminary scientific Programme

thelatestinternationalfindingsregardingtmSfortreatingdepressionChair: PaulFitzgerald,AustraliaCo-Chair: MarkGeorge,USA

newdataonacutephasetreatments–dosingparadigms,improvingspeedofresponse,coildesignsPaulFitzgerald,Australia

HowdurablearetmSantidepressanteffects?newdataMarkDemitrack,USA

CombiningtmSwithCBtormedicationstoboostresponseMichaelThase,USA

thelatestadvancesinunderstandingtmSantidepressantneurobiologyShinsukeKito,Japan

suicide: BAsic / clinicAl

moleculardeterminantsofsuicideChair: GhanshyamPandey,USACo-Chair: JohnMann,USA

ImagingstudiesofsuicidalbehaviorneuralcircuitryJohnMann,USA

neuroinflammatory markers in suicide brain: Focus oncytokinereceptorsandtoll-likereceptorsGhanshyamPandey,USA

epigenomicbasis forastrocyteabnormalities insuicidalbehaviorGustavoTurecki,Canada

roleofmicrornAsintheetiologyandtreatmentofde-pressivedisorderandsuicideYogeshDwivedi,USA

translationalpsychiatryinmooddisordersandsuicideChair: JulioLicinio,AustraliaCo-Chair: PhilippeCourtet,France

ImagingandcognitivemarkersofsuicidalbehaviorFabriceJollant,Canada

omicspredictorsofsuicidalbehaviourEnriqueBacaGarcia,Spain

theroleofneuroinflammationandimmunityonsuicidalityPhilippeCourtet,France

Serotonin and endocannabinoid system in mood disor-ders:AnimalandclinicalstudiesGabriellaGobbi,Canada

WFSBP 2015

20

Preliminary scientific Programme / Workshops

WorKSHoPS

BipolAr disorders: BAsic / clinicAl

lithiumphobia:Scienceorsuperstition?Chair: DigvijayGoel,NewZealandCo-Chair: MohanIsaac,Australia

lithium:Scienceorsuperstition?DigvijayGoel,NewZealand

lithium:themagicionShaileshKumar,NewZealand

lithiumvs.sodiumvalproate:understandingthedilemmaRajeshNagpal,India

lithium:thewayforwardsMohanIsaac,Australia

mooddisordersandbipolarspectrum:HowtogetoverdiagnosticproblemsChair: GiuseppeTavormina,ItalyCo-Chair: NicolasZdanowicz,Belgium

Bipolarityduringtheadolescence:limitsoftheconceptNicolasZdanowicz,Belgium

depressionandworkrelatedstressproblemsMarilisaAmorosi,Italy

depressivedisordersandresilienceSandroElisei,Italy

evaluation of cases reports of bipolar spectrum mixedstates:Adiagnostic-therapeuticapproachGiuseppeTavormina,Italy

AlatinAmericancontributiontobipolardisordersChair: EugenioVargasPena,ParaguayCo-Chair: GuillermoDorado,Argentina

KraepelinmodelinbipolardisordersJaimeVengoechea,Colombia

AddictivedisordersandbipolarityGuillermoDorado,Argentina

BipolarIIdisordersandsuddenepisodicdepressionEugenioVargasPena,Paraguay

Commentsonbrain-SPeCtandbipolardisordersEnriqueGalli,Peru

childhood & Adolescent disorders: BAsic / clinicAl

evaluationandmanagementofyouthwithautismspectrumdisordersandco-morbidbehavioralandneurologicsymptomsChair: AdelaideRobb,USACo-Chair: PeterDaniolos,USA

multidisciplanaryteamevaluationofyouthwithautismPeterDaniolos,USA

treatmentofdisruptivebehaviorandaggressioninautismAdelaideRobb,USA

recognitionandmanagementofepilepsyinautismWilliamGaillard,USA

use of telehealth to increase accessibility of evidence-basedinterventionforchildrenwithPddToddKopelman,USA

cognitive neuroscience

neurocognitiveandfunctionalimpairmentinmooddisordersChair: SagarParikh,CanadaCo-Chair: RoumenMilev,Canada

neurocognitivedeficitsinmooddisorders:Biologicalun-derpinningsBenicioFrey,Canada

Clinicalassessmentofneurocognition:thebasisforim-provedclinicaloutcomesMichaelBerk,Australia

neurocognitiveand functionaloutcomes inbipolardis-ordersSergeBeaulieu,Canada

neurocognitiveandfunctionaloutcomesindepressionArunRavindran,Canada

Patient’sresponsetotreatment:AneurobiologicalapproachChair: JorgeTellez-Vargas,ColombiaCo-Chair: PolicarpoRebolledo,Chile

InflammatoryandmetabolicdysregulationaspredictorofantidepressantresponseJorgeTellez-Vargas,Colombia

Seekingrelief:theactivationofmotivationalandrewardcircuitsRubyCastilla-Puentes,USA

PharmacogeneticsstudiesinlatinAmericaHernanSilva,Chile

GeneticandpsychiatricdiagnosisVeronicaLarach,Chile

21

WFSBP 2015

Workshops / Preliminary scientific Programme

dementiA

developmentofbiologicalmarkersfordifferentialdiagnosisofdementiainphysiologicalandbiochemicalstrategiesChair: ToshihisaTanaka,JapanCo-Chair: FernandoMaestu,Spain

magnetoencephalographyfordiagnoseandevaluationofdementiaFernandoFernando,Spain

FunctionalconnectivityineeGfordiagnosisofAlzheimerdiseaseLeonidesCanuet,Spain

Screeningofcognitiveimpairmentanddiagnosisofde-mentiaKatsuyaUrakami,Japan

CSFbiomarkersindifferentialdiagnosisofdementiaToshihisaTanaka,Japan

depression: BAsic / clinicAl

roleofaldosteroneandmineralocorticoidreceptorfunctioninemotion-regulationChair: HaraldMurck,USACo-Chair: AlanKimJohnson,USA

AldosteroneinstressrelateddepressionmodelsMikeFranklin,UnitedKingdom

Sodiumdeficiencyandmood:thebrainrenin-angioten-sin-aldosteronesysteminthecravingforsaltandinan-hedoniaAlanKimJohnson,USA

AldosteroneandmineralocorticoidfunctionaspredictorsofantidepressantresponseHaraldMurck,USA

theroleofmineralocorticoidreceptorsinemotionalre-gulationinborderlinepersonalitydisorderKatjaWingenfeld,Germany

taskforcerecommendationsforthemanagementofcomorbidityinmajordepressivedisorderandbipolardisorderChair: RogerMcIntyre,CanadaCo-Chair: RoumenMilev,Canada

Generalprinciplesofmanagingcomorbidity:AfocusonmedicalcomorbidityRogerMcIntyre,Canada

managementofpatientswithcomorbidmoodandanxi-etydisordersAyalSchaffer,Canada

managingsubstanceuseinmooddisordersSergeBeaulieu,Canada

treating bipolar disorder in the real world integratingcomorbidityintotreatmentdecisionsAllanYoung,UnitedKingdom

neurophysiology

transcranialmagneticstimulationstudiesofneurophysiology,neuroplasticity,andneurocognitioninpsychiatricdisordersChair: PaulCroarkin,USACo-Chair: ZafirisDaskalakis,Canada

overviewoftranscranialmagneticstimulationstudiesinseverepsychiatricdisordersZafirisDaskalakis,Canada

tmSstudiesofborderlinepersonalitydisorderandchronicpainShirleneSampson,USA

rtmSstudiesofneurocognitioninschizophreniaAristotleVoineskos,Canada

theneurochemistryoftmS:magnetic resonance spec-troscopystudiesJohnDPort,USA

oBsessive-compulsive disorders: BAsic / clinicAl

Biologicalapproachestowardclarifyingheterogeneitiesofobsessive-compulsivedisorderChair: TomohiroNakao,JapanCo-Chair: HisatoMatsunaga,Japan

Altered frontostriatal connectivity in obsessive-compul-sivedisorderTakashiNakamae,Japan

neurobiologicalheterogeneitiesofoCdTomohiroNakao,Japan

Cross-culturalaspectsofsymptomdimensionofoCdHisatoMatsunaga,Japan

does the neurobiology of obsessions and compulsionsdiffer?DamiaanDenys,TheNetherlands

WFSBP 2015

22

Preliminary scientific Programme / Workshops

posttrAumAtic stress: BAsic / clinicAl

InteractionbetweenneurobiologicalandethnoculturalfactorsinPtSdtreatmentresponse,recoveryandresilience.Istherealink?Chair: SorayaSeedat,SouthAfricaCo-Chair: MushtaqMargoob,India

Contributionofethnocultural,geneticandbiologicalfac-torstoincreasingordecreasingPtSdtreatmentresponse–anAsianexperienceMushtaqMargoob,India

Contributionofethnocultural,geneticandbiologicalfac-torstoincreasingordecreasingaperson’sriskfordevel-opingPtSdonceheorshehasbeenexposedtotrauma–anAfricanexperienceSorayaSeedat,SouthAfrica

AmodelofsuicidalbehavioramongimmigrantswithPtSdLeoSher,USA

BdnFgenetics,serumBdnF,andethnicity:ImplicationsforinterveninginPtSdSorayaSeedat,SouthAfrica

schizophreniA: BAsic / clinicAl

metabolicdisturbancesinschizophrenia:epidemiology,pathophysiologyandantipsychotics–towardsclinicalapplicationofgeneticriskmodelsandnewtreatmentstrategiesChair: WiepkeCahn,TheNetherlandsCo-Chair: BjørnH.Ebdrup,Denmark

Antipsychotic-associated dysmetabolism: Glucometabo-lichormones,cardiovascularriskmarkersandpotentialphysiologicalbenefitsofglucagon-likepeptide-1receptoragonisttreatmentBjørnH.Ebdrup,Denmark

nationwidestudiesofdiabetesinpsychiatricpopulationsRenéE.Nielsen,Denmark

Antipsychotic-inducedglucosedisturbances:FrommicetomenMargaretHahn,Canada

GWAS in antipsychotic-induced weight gain dissectingtheCAtIesampleDanielJ.Müller,Canada

treatmentofschizophrenia:PersonalizedtailoringtomeetpatientsneedsChair: KonstantinosFountoulakis,GreeceCo-Chair: CyrilHoschl,CzechRepublic

Antipsychotics:differencesandspecificityAlessandroSerretti,Italy

InformationtechnologyinthemanagementofschizophreniaCyrilHoschl,CzechRepublic

Computer-assistedtreatmentpathwayforschizophrenia:developmentandfirstresultsinover200patientsGeorgJuckel,Germany

theoptimizationeffectinschizophrenia:Whyweseedif-ferentthingsineverydayclinicalpracticeKonstantinosFountoulakis,Greece

suicide: BAsic / clinicAl

PathwaysassociatingstresstotheneurobiologyofsuicideChair: LeoSher,USACo-Chair: JorgeOspina-Duque,Colombia

Aneurobiological stress-diathesismodelof suicidalbe-haviorLeoSher,USA

Stress and suicide: the role of the hypothalamic-pitu-itary-adrenalaxisM.DoloresBraquehais,Spain

relationbetweenstress,serotonin,andsuicideMushtaqMargoob,India

oxytocininsuicidalbehaviorJussiJokinen,Sweden

SuicideandbehavioraladdictioninKorea:SearchingforthebiopsychosocialbasisinthefastchangingsocietyChair: ChangUkLee,RepublicofKoreaCo-Chair: HanYongJung,RepublicofKorea

Crossculturaldifferences in theattitudetowardsuicide:multi-countriescomparisonstudyYongMinAhn,RepublicofKorea

PostventionprogramforsuicideattemptersinSeoulJong-WooPaik,RepublicofKorea

GeneticneuroimagingstudytofindtheneurobiologyofdepressivedisordersByungjooHam,RepublicofKorea

neurobiologyofimpulsivebehaviorsandbehavioralad-dictionsDai-JinKim,RepublicofKorea

23

WFSBP 2015

Topics

The scientific programme of the WFSBP 2015 Congress will cover the following topics, within each topic the track may be Basic, Clinical, Interface or Conceptual:

1. Addictive Disorders2. Antidepressants: Basic / Clinical3. Antipsychotics: Basic / Clinical4. Anxiety Disorders: Basic / Clinical5. Anxiolytics: Basic / Clinical6. Bipolar Disorders: Basic / Clinical7. Childhood & Adolescent Disorders: Basic / Clinical8. Cognitive Neuroscience9. Dementia: Basic / Clinical10. Depression: Basic / Clinical11. Eating Disorders: Basic / Clinical12. Emergency Psychiatry13. Epidemiology14. Ethics and Psychiatry15. Forensic Psychiatry16. Genetics17. Hypnotics: Basic / Clinical18. Liaison Psychiatry19. Mental Retardation or Chromosomal Aberrations:

Basic / Clinical20. Molecular Neurobiology21. Mood Stabilisers: Basic / Clinical22. Neuropathology23. Neuroimaging: Genetic, Functional, Structural

24. Neurophysiology25. Obsessive-Compulsive Disorders: Basic / Clinical26. Oncopsychiatry27. Pain: Basic / Clinical28. Panic Disorders: Basic / Clinical29. Personality Disorders: Basic / Clinical30. Pharmacoeconomics31. Pharmacogenetics32. Pharmacology33. Posttraumatic Stress: Basic / Clinical34. Pregnancy, post partum and new born: Basic / Clinical35. Premenstrual Syndrome: Basic / Clinical36. Psychogeriatrics37. Psychoneuroimmunology38. Psychopathology39. Psychosurgery40. Schizophrenia: Basic / Clinical41. Sexual Disorders: Basic / Clinical42. Sleep Disorders: Basic / Clinical43. Somatoform Disorders: Basic / Clinical44. Stimulation Methods (ECT, TMS, VNS, DBS)45. Stress: Basic / Clinical46. Suicide: Basic / Clinical47. Violence: Basic / Clinical

WFSBP 2015

24

Call for Abstracts for free Communications and Posters

deadline for abstract submission: 10 december 2014notificationofacceptance/rejection:march2015

Authors of Free Communications or Posters are hereby kindly invited to submit an abstract for contributions to the WSFBP 2015 Congress by using the online submission form on the congress website www.wfsbp-congress.org. Please note that online submission is mandatory. Free Communications and Posters submitted individually and accepted by the International Scientific Programme Committee will be grouped by category topics into the-matic sessions in order to promote communication among the presenters and participants and to allow for inspiring discussions.

FreeCommunICAtIonSThe Free Communications will be selected by the Internati-onal Scientific Programme Committee after abstract sub-missions have been reviewed. The 90-minutes sessions will be grouped by topics and chaired by selected specialists. The time slot for a single presentation in a Free Communi-cation session is 15 minutes including discussion time. only1FreeCommunicationabstractmaybesubmittedperauthor.

PoSterSEach accepted poster will be exhibited at the WFSBP 2015 Athens Congress in the Muses Foyer of the Megaron Athens International Conference Centre. The best posters will be grouped into thematic Guided Poster Tours chaired by re-nowned specialists. The Guided Poster Tours will give the authors the opportunity to present their findings and dis-cuss them with the audience. A maximum of 4 postersabstractsmaybesubmittedperauthor.The congress will deliver WFSBP young InvestigatorAwards for the five best posters. Please refer to page 26 for further information.

Please note that accepted abstracts will be published only after completed registration and payment of the congress registration fee. The acceptance of submitted abstracts si-multaneously results in binding registration of the speaker to attend the conference. theregistrationfeemustbepaid immediately after receiving the abstract acceptance, latestuntil1April2015. Authors who have not settled the regis-tration fee until that date will be omitted from the scientific programme. onsiteregistrationforpresentingauthorsisnotpossible.

GuIdelIneSFortHePrePArAtIonoFABStrACtSPlease submit your abstracts online and in English, the offi-cial language of the WFSBP Congress 2015.

U Please choose a title that clearly indicates the content of the contribution.

U Please avoid abbreviations in the title. Abbreviations may be used in the text if they are defined when used first.

U The author’s name (full first name, family name) and place of work (institution, city, country) should be given. Degrees, titles, street addresses, and acknowledgements of support should be omitted, however.

U The abstract submission must be complete.U Please choose a topic from the topic list, page 23.U The text of the abstract should briefly state: objectives

(indicate the purpose of the study or the hypothesis that was tested), methods (include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis), results(present as clearly as possi-ble the outcome of the study and statistical significance if appropriate) and Conclusions (briefly discuss the data and emphasise the significance of the results). References need to be given in the text.

U The length of your abstract is limited to a maximum of 300 words.

U Please ensure that the abstract does not contain spelling, grammar or scientific errors, as it will be reproduced ex-actly as submitted. Submitted abstracts will not be edited in any way. If the abstract does not fulfil the necessary requirements it cannot be published.

U A disclosure of the existence of any significant financial interest or other affiliations with a funding organisation or with a commercial supporter of the session and / or provi-der of commercial services is required.

U All abstracts will be published online in the scientific pro-gramme of the WFSBP Congress from April 2015.

U only1FreeCommunicationAbstractmaybesubmit-tedperauthor.

U Amaximumof4postersmaybesubmittedbyeachauthor.

25

WFSBP 2015

format Descriptions of the scientific sessions

oPenInGleCtureThe Opening Lecture will be held during the Opening Ce-remony on 14 June 2015.

PlenAryleCtureSPlenary Lectures are 45-minute sessions held by renowned experts. The speakers have been chosen from among the most prominent researchers in the respective field.

SymPoSIASymposia are selected, covering basic, clinical, interface and conceptual topics of Biological Psychiatry. Symposia will be organised and chaired by the experts whose propo-sals are accepted by the International Scientific Programme Committee.

WorKSHoPSWorkshops are highly interactive sessions with an educatio-nal focus. This format is especially designed to give specific regions a platform for presentation and networking.

deBAteSDebates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) will state their opinions on different subjects.

WFSBPtreAtmentGuIdelIneSTreatment Guidelines Sessions are 90-minute sessions with an educational focus. They centre on the WFSBP Treatment Guidelines and include brief presentations by individual pa-nel members, followed by lively and informative discussion. This session type provides for substantial audience participa-tion and should be highly interactive.

FreeCommunICAtIonSAuthors will be invited to submit abstracts on their latest research findings. All submitted abstracts will be reviewed and the best will be selected and allocated to Free Commu-nication Sessions.

GuIdedPoStertourSA whole range of highly interesting papers on new research findings and / or major research efforts are expected to be submitted as posters. As many posters will probably be sub-mitted by young investigators, the Local Organising Com-mittee will arrange Guided Poster Tours to give the authors the opportunity to present these findings and discuss them with the audience.

CmeACCredItAtIonAn application will be made to the EACCME® for CME accreditation of this event.

WFSBP 2015

26

WfsBP Awards

The following WFSBP Awards will be delivered and presen-ted during the 12th World Congress of Biological Psychiatry 2015 in Athens.

U WFSBP lifetime Achievement Award in BiologicalPsychiatry

The WFSBP Lifetime Achievement Award in Biologi-cal Psychiatry is intended for senior research scientists (MD, PhD or equivalent) whose lifework has sig-nificantly influenced today‘s field of biological psychi-atry. This award is open to members and non-mem-bers of the WFSBP. It consists of a monetary award of EUR 1,000.

U WFSBPAwardforScientificexcellenceoftheWFSBPHost

The WFSBP Award for Scientific Excellence of the WFSBP Host is dedicated to an outstanding resear-cher in the field of Biological Psychiatry originating from the host country of the World Congress of Biolo-gical Psychiatry. This award consists of a monetary award of EUR 1,000.

U WFSBPresearchPrize The WFSBP Research Prize is intended for WFSBP

members (MD, PhD or equivalent) whose current sci-entific work has had an important impact in the field of clinical and/or basic research in the area of biologi-cal psychiatry. This prize consists of a monetary award of EUR 1,000.

U WFSBPAwardforexcellenceineducation The WFSBP Award for Excellence in Education is to

acknowledge outstanding and innovative education in biological psychiatry including the implementa tion of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved the education in all fields of Psychiatry. This award consists of a monetary award of EUR 1,000.

Please note that presenting authors must register and attend the meeting to be eligible for any of these awards.

Applications must be sent by e-mail to the congress and exhibition office:

Hamburg OfficeHanser & Co GmbHZum Ehrenhain 34 Phone: +49 – 40 – 670 88 20Fax: +49 – 40 – 670 32 83Email: wfsbp2015@cpo-hanser.de

by10december2014 and should include a short summary of the work and a brief CV. The letter should outline the main professional activities and provide key peer review pu-blications. Prizes will be announced during the Opening Ceremony.

U WFSBPyoungInvestigatorAwardsforthefivebestposters(under40year-old)

An application for the Young Investigator Award is not necessary. All posters will be evaluated at the con-gress. The awards will go to those presentations that not only provide evidence of innovative research, but which are also well presented.

Please note that presenting authors must register and attend the meeting to be eligible for this award. Poster prizes will be delivered during the Closing Ceremony.

27

WFSBP 2015

Congress Information

Please register online for the WFSBP 2015 Athens Congress. Simply complete the registration form available on the Inter-net: www.wfsbp-congress.orgor make use of the registration form enclosed at the end of this document.

PAymentWhen registering for the WFSBP 2015 Congress in Athens, please arrange for payment of the registration fee. All pay-ments should be made in EURO. You may choose between two modes of payment: credit card payment or bank transfer. Especially for payment made from outside Germany where the congress office is based, we strongly recommend credit card payments as charges for bank transfers may apply twice, once in the country of origin and a second time in Germany.

Please choose one mode of payment: Creditcard: AMEX, Eurocard / Mastercard or VISA orBanktransfertothecongressbankaccount:CPO HANSER SERVICE w / WFSBP ZB 2015HSH Nordbank AG / Bank Code: 210 500 00Account Number: 1001 2458 74BIC: HSHNDEHH / IBAN: DE06 2105 0000 1000 2458 74

ConFIrmAtIonUpon receipt of the registration and the corresponding pay-ment, the congress office will send a confirmation form which also serves as an invoice. Please show this confirma-tion of registration at the congress counter when picking up your congress materials.

CAnCellAtIonoFConGreSSPArtICIPAtIonNotice of cancellation should be sent in writing only to the Congress Office CPO HANSER SERVICE. In case of cancel-lation by 28 January 2015 the payment will be refunded, minus a handling charge of 25%. No refund will be made after 28 January 2015.

on-SItereGIStrAtIonAFter2june2015On-site registration will be possible but we recommend to register well in advance. Participants who wish to register on-site are advised to arrive early. On-site registration does not entitle participants to receive a delegate bag. On-site regis-tration will be handled on a first-come, first-served basis, priority will be given to pre-registered delegates.

Registration and payment received

Early registration by 28 January 2015

EUR

Late registration by 2 June 2015

EUR

On-site registration after 2 June 2015

EUR

WFSBP Members 530 630 730

Non-Members 630 730 830

Greek Psychiatrists*** 480 570 660

Participants from Low-Income Countries* 290 390 490

Trainees** 290 390 490

Greek Students** 170 230 290

Congress Registration for the 12th World Congress of Biological Psychiatry is available via the congress website at www.wfsbp-congress.org.

* According to the Low-Income-Countries defined by the world bank. Please see the list on the WFSBP website www.wfsbp-congress.org** Trainee / Student status must be confirmed by certificate in writing by head of department and is applicable only for participants born after

1 Jan 1980. Please send your certificate by email or fax to: Hanser & Co GmbH, Fax: +49 – 40 –670 32 83, Email: wfsbp2015@cpo-hanser.de*** Psychiatrists resident in Greece.

WFSBP 2015

28

General Information

ConGreSSVenueMegaron Athens International Conference CentreLeoforos Vasilissis Sofias and Kokkali 1Athens 115 21, Greece

ConGreSSreGIStrAtIondeSKThe congress counter will be located in the Mitropoulos Foyer, on the right hand side of entrance B of Megaron Athens International Conference Centre, which is the main entrance area for the WFSBP 2015 Congress.

Preliminaryopeninghours

Sunday, 14 June 2015 12:00 – 19:00

Monday, 15 June 2015 07:30 – 18:30

Tuesday, 16 June 2015 08:00 – 18:30

Wednesday, 17 June 2015 08:00 – 18:30

Thursday, 18 June 2015 08:00 – 17:00

ConGreSSAndexHIBItIonoFFICe

Hamburg OfficeHanser & Co GmbHZum Ehrenhain 34 22885 Barsbüttel, GermanyPhone: +49 – 40 – 670 88 20Fax: +49 – 40 – 670 32 83Email: wfsbp2015@cpo-hanser.de

PoSterexHIBItIonPosters will be displayed from Monday, 15 June to Thurs-day, 18 June 2015 in the Muses Foyer nearby the technical exhibition. Each congress day there will be one Guided Po-ster Tour with the best posters only. The posters selected for the Guided Poster Tour will be displayed in a special area of the congress centre. During the review of the abstracts which is done by the Local Organising Committee, the re-viewers will indicate the candidates for the Guided Poster Tours. All other posters will be displayed for one entire con-gress day and grouped according to topics.

Information regarding poster format, set-up and dismant-ling will be sent to the authors along with their notification of acceptance.

teCHnICAlexHIBItIonThe WFSBP Congress 2015 will be accompanied by a ma-jor technical exhibition taking place in the Muses Foyer of the Megaron Athens International Conference Centre. Po-tential exhibitors can request an exhibition/sponsoring bro-chure from the exhibition office CPO HANSER SERVICE.Email: wfsbp2015@cpo-hanser.de

Preliminaryopeninghours

Monday, 15 June 2015 09:00 – 17:00

Tuesday, 16 June 2015 09:00 – 17:00

Wednesday, 17 June 2015 09:00 – 17:00

ConGreSSInFormAtIonSyStem/CoConGreSSonlIne®

The web based Congress Information System CO CON-GRESS ONLINE® has been installed atwww.wfsbp-congress.org

Prior to the congress, CO CONGRESS ONLINE® will provi-de information on:U Preparation of the congressU List of topicsU Call for abstractsU Invited speakers and invited conveners of symposiaU Preliminary scientific programmeU Accepted abstractsU List of participants (who is who)U List of exhibitorsU Information about the main sponsorsU AthensU Hotel accommodationU Travel to AthensU Special newsU Private mailbox

In due time, the final programme will be published on CO CONGRESS ONLINE® which enables each participant to create her / his personal congress programme schedule. CO CONGRESS ONLINE® offers an extensive congress service.

29

WFSBP 2015

General Information

FInAlProGrAmmeThe final programme and abstracts will be published on the Internet at www.wfsbp-congress.org prior to the congress.

WFSBP2015ConGreSSAPPmoBIleThe WFSBP 2015 Congress App is free for congress partici-pants and provides iPhone/iPad, android and other smart-phone users at WFSBP 2015 in Athens with on-the-go ac-cess to the congress. The most up-to-date congress schedule is available at the fingertips during the congress. Available for download prior to WFSBP 2015 – powered by GLOBIT’s acclaimed CONGRESS MOBILE software.

ConGreSSlAnGuAGeThe official language of the WFSBP Congress 2015 is English. Simultaneous translation will not be provided.

letteroFInVItAtIonThe congress will be pleased to send a formal letter of invi-tation to any registered delegate requesting one. It is under-stood that such an invitation is intended to help potential delegates to raise funds or to obtain a visa. This does not imply a commitment from the congress to provide any fi-nancial support. Letters of invitation may be requested from the congress office.

VISAThe entry formalities for Greece vary according to the country of origin. The Ministry of Foreign Affairs of Greece advises on its website a list of countries that do not and that do require a visa to enter the country. Please visit the web-site www.mfa.gr.

oFFICIAlItAlIAnAGenCyForItaliandelegatesonly:AIM Group International – AIM Education S.r.l. has been appointed as the Italian Official Agency for AIFA submissi-on. Italian pharmaceutical companies which require spe-cific authorisation from the Italian Health Ministry are ad-vised to contact:

AIM Group International – AIM Education S.r.l.Raffaella Figerio / Cristina GhidoliVia G. Ripamonti, 129 l 20141 Milan, ItalyPhone: +39 – 02 – 56601.288/360Fax: +39 – 02 – 70048585Email: aifa@aimgroup.euwww.aimgroupinternational.com

InSurAnCePlease notice that the congress fee does not include insu-rance. All participants should arrange for their own insu-rance. Health and accident insurance is strongly recommen-ded and will need to be purchased in the country of origin.

ForCemAjeureFor reasons beyond its control (such as war, strikes, lock-outs, riots or any such civil disturbances, any natural di-saster, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circum-stance of whatsoever nature beyond control) that have an impact on the arrangements, timetables or planning of the 12th World Congress of Biological Psychiatry (WFSBP 2015) and its corresponding activities in Athens, WFSBP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

CurrenCyThe Greek Currency is Euro (€). The euro is freely converti-ble on world currency markets. The exchange rate fluctu-ates daily depending on the money market.

ClImAteThe city of Athens is located in a Mediterranean climate. The average temperature for the month of June is 28 °C / 82 °F and it can drop down to 20 °C / 68 °F. The sun shines 13 hours a day. The sun’s rays are strong and it is recommended to use sun-cream and to wear a hat and sunglasses. A bottle of water should be taken with you every time you go outside to keep yourself appropriately hydrated. In average it rains 4 days in the month of June.

AIrPortThe Athens-Eleftherios Venizelos Airport (ATH) is the inter-national airport of the city Athens. It is named after the pre-mier Eleftherios Venizelos (1864 – 1936) and is the biggest and most important airport of Greece. The airport functions as an intersection for the Middle East and the Balkans. More than 13 million travelers transfer via the ATH yearly. It is 25 kilometers away from the city center and part of the commune Spata.

WFSBP 2015

30

General Information

trAnSPortBetWeenAIrPortAndCIty/CItyAndmeGAronAtHenSInternAtIonAlConFerenCeCentreThe metro M3 takes about 30 minutes from the airport to the Meragon Athens International Conference Centre (me-tro station “Megaron Moussikis” on metro line 3 (blue line). Please visit the website www.ametro.gr for more informati-on about the prices and departure times.

HouSInGAndloCAlAGenCyFor the 12th WFSBP Congress, the hotel accommodation and organised tours will be realised by our on-site partner company AFEA.

AFeAS.A.39-41 Lykavittou Str. •10672 Athens, Greece Email: wfsbp2015@afea.grPhone: +30 – 210 3668800Contact: Martha Kornarou

PleasebookyourhotelandtoursonlinewithAFeA.As the official housing agency for WFSBP AFEA has secured a variety of hotels that range from luxurious to more stan-dard accommodations. Whether in downtown Athens, or in the direct surrounding of the Megaron International Conference Centre, there is a hotel for every taste, budget and need. AFEA has negotiated special rates for congress delegates. As June is a high season in Athens we kindly ad-vise all delegates and speakers to make their bookings well in advance.

All hotels are available online via congress website:www.wfsbp-congress.org

CItyoFAtHenSLocated in the very southeast of Europe, Greece – ‚Hellas‘ – is one of the oldest cultural spot within Europe. With a total population of around 11,3 million people, more than a third – 4 million people – live in Athens, the Capital. Athens is located in the Attica prefecture, in particular in the Attica basin, which is framed by Mount Aegaleo, Mount Parnitha, Mount Penteli and Mount Hymettos.

Athens has been founded more than 5,000 years ago and therefore is – unchallenged – the oldest and most ancient capital in Europe. But not only is the age a measure. Nowa-days Athens is a very special spot in the world where ancient culture meets the challenges and advantages of todays life.

This was proved very successfully by the Olympic summer games in 2004. Athens has come up with infrastructure, facilities and services that meet global standards – so far the 12th World Congress of Biological Psychiatry will become another successful global event in a global environment.

Next to the most famous sites of Athens, such as the Acro-polis, the National Archaeological Museium of Athens, the Museum of the Acropolis, the Plaka area, also known as the god´s neighborhood. Athens is very famous for the attic light, a unique yellow golden light which has been descri-bed since ancient times.

Also in scientific terms, Greece and especially Athens have much going for: Nine universities are located in Athens. In the 20th century, two Nobel Prize of Literature awardees were born in Greece: Odysseas Elytis (1911-1996), recei-ved the prize in 1979 – and Giorgos Seferis (1900-1971), who was the awardee of 1963.

Attend the 12th Congress of the World Federation of Biolo-gical Psychiatry and see for yourself what else Athens and Greece have to offer.

31

WFSBP 2015

Notes

WFSBP 2015

32

Notes

Dates to remember

10 December 2014 Abstract submission for posters and free communications

28 January 2015 Deadline early bird registration

14 June 2015 Opening Ceremony, and Reception and Networking Event

www.wfsbp-congress.org